A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
This research study is investigating a new medication, ARO-APOC3, for adults who have a condition called "mixed dyslipidemia." This means they have unhealthy levels of different types of fats and cholesterol in their blood, which can increase their risk of heart problems. The main aim of this study is to observe the long-term safety of ARO-APOC3. This involves carefully monitoring participants for any side effects that might occur. The study also wants to understand how effective the medicine is at lowering various types of fats and cholesterol in the blood over time. This includes levels of triglycerides, different forms of cholesterol, and other related substances. By gathering this information, researchers hope to learn more about how this new treatment could help people manage their blood fat levels.
At a glance
What is this study about?
This research study is focused on a health condition called 'mixed dyslipidemia'. Simply put, this means that someone has an unhealthy mix of fats and cholesterol in their blood. For example, they might have high levels of triglycerides (a type of fat) and 'bad' cholesterol (LDL-C), and sometimes low levels of 'good' cholesterol (HDL-C). Having these imbalanced levels can increase a person's risk of developing heart disease or having a stroke over time. Current treatments can help, but researchers are always looking for new and potentially better ways to manage this condition.
The new medicine being tested in this study is called ARO-APOC3. This is what's known as an 'open-label extension study', which means participants and their doctors will know they are receiving the study medicine. It's a 'Phase 2' study, which means it's still relatively early in the development of the medicine. At this stage, researchers are trying to get a better understanding of how the medicine works, what dosage is best, and if it's safe for long-term use, alongside checking its effects on blood fat levels.
The main goal of this particular study is to check the safety of ARO-APOC3 over a longer period. This involves carefully looking for any side effects or unwanted reactions that might happen while people are taking the medicine. Researchers will also closely observe if and how well ARO-APOC3 helps to reduce the unhealthy fats and cholesterol in the blood. They will measure various types of fats and cholesterol, including triglycerides, HDL-C, and LDL-C, to see if the medicine makes a positive difference.
Key takeaways
- This study is testing a new medicine (ARO-APOC3) for high blood fats and cholesterol.
- The main goals are to check its long-term safety and how well it lowers unhealthy fat levels.
- It's open to adults aged 18 and over who have mixed dyslipidemia.
- Participation involves taking the study medicine and having regular health checks and blood tests.
- You will know you are receiving the study medicine.
Who may be eligible?
This study is designed for adults aged 18 and older. There is no upper age limit, so older adults can also take part.
Both men and women are welcome to participate in this study. The research aims to understand how the medicine works across different people.
To be eligible, you must have been diagnosed with mixed dyslipidemia. This means your doctor would have told you that you have an unhealthy balance of fats and cholesterol in your blood. Other specific medical requirements will be checked by the study team to ensure the study is right for you and safe for you to join.
- Are you 18 years old or older?
- Have you been diagnosed with a condition called mixed dyslipidemia (unhealthy blood fats and cholesterol)?
- Are you able to attend regular appointments for checks and blood tests?
- Are you comfortable knowing you will receive the experimental study medicine?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would receive the study medicine, ARO-APOC3. You would have regular appointments at the study clinic, likely involving blood tests to check your blood fat levels and monitor for any side effects. Your overall health would also be regularly checked by the study team. The total time you would be involved in the study isn't specified here, but clinical trials usually involve a number of visits over several months or even a few years for long-term safety studies.
Potential risks and benefits
Locations (3)
- —Poland
- —Hungary
- —Netherlands
Common questions
What is mixed dyslipidemia?
It's a common condition where you have high levels of unhealthy fats (like triglycerides) and cholesterol in your blood, which can increase heart disease risk.
What is ARO-APOC3?
It's a new, investigational medicine being tested in this study to see if it can help lower unhealthy blood fat levels.
Is this medicine approved for general use?
No, ARO-APOC3 is currently an investigational medicine, meaning it's still being studied and is not yet approved for general use.
What is a 'Phase 2' study?
It means the medicine is still in early development. Researchers are looking at its safety and how well it works before considering larger studies.
Will I know if I'm getting the actual medicine?
Yes, in this 'open-label' study, both you and your doctor will know that you are receiving the ARO-APOC3 medicine.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.